Morphine

UDP glucuronosyltransferase family 2 member B7 ; Homo sapiens







65 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33847389 Pharmacogenomics and Morphine. 2021 Sep 2
2 33008919 Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity. 2020 Dec 1
3 30300922 Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. 2019 Mar 2
4 30421550 Prolonged central apnoea after intravenous morphine administration in a 12-year-old male with a UGT1A1 loss-of-function polymorphism. 2019 Jan 1
5 30709768 Morphine biotransformation genes and neonatal clinical factors predicted behaviour problems in very preterm children at 18 months. 2019 Feb 1
6 31607718 Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese han population. 2019 Oct 6
7 29164523 Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes. 2018 Jun 1
8 29172026 Effect of non-prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes. 2018 Jun 1
9 29241692 In vitro inhibitory effects of major bioactive constituents of Andrographis paniculata, Curcuma longa and Silybum marianum on human liver microsomal morphine glucuronidation: A prediction of potential herb-drug interactions arising from andrographolide, curcumin and silybin inhibition in humans. 2018 Feb 1
10 29363349 Drug metabolism in early infancy: opioids as an illustration. 2018 Mar 1
11 29695616 Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. 2018 Jul 1
12 29920988 PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants. 2018 Jul 2
13 28063968 Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. 2017 Mar 1 1
14 28418861 Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor. 2017 Apr 25 3
15 28552915 The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants. 2017 Aug 5
16 26751618 Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. 2016 Mar 7 1
17 27847477 Reverse of Acute and Chronic Morphine Tolerance by Lithocholic Acid via Down-Regulating UGT2B7. 2016 6
18 28256933 Association between UGT2B7 gene polymorphisms and fentanyl sensitivity in patients undergoing painful orthognathic surgery. 2016 Jan-Dec 2
19 25713207 Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells. 2015 May 1
20 25770680 Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity. 2015 May 1 1
21 26053558 In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. 2015 2
22 24459244 Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. 2014 Apr 3
23 24703092 Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption. 2014 Nov 3
24 25340733 Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. 2014 5
25 25278738 Pharmacogenomics study in a Taiwan methadone maintenance cohort. 2013 Dec 1
26 22240840 The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. 2012 2
27 22430884 Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. 2012 May 1
28 22435749 Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities. 2012 Sep 2
29 19466410 Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. 2010 Jan 2
30 20071451 Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. 2010 Apr 1
31 17722074 Pharmacogenetics of morphine: Potential implications in sickle cell disease. 2008 Mar 1
32 17724700 UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. 2008 Mar 7
33 18187562 Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. 2008 Apr 5
34 17495417 Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. 2007 Apr 2
35 16381668 Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. 2006 Mar 1
36 16679387 Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. 2006 Aug 4
37 15611481 Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. 2005 Mar 6
38 16045647 Genetic variability and clinical efficacy of morphine. 2005 Aug 3
39 16103897 Clinical response to morphine in cancer patients and genetic variation in candidate genes. 2005 2
40 16215614 [Genetic variation-- important for the clinical effect of opioids?]. 2005 Oct 6 1
41 15001974 A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. 2004 Mar 3
42 12629580 Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. 2003 2
43 12657745 Glucuronidation of 1'-hydroxyestragole (1'-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. 2003 May 1
44 12695358 Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. 2003 May 2
45 12756209 The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. 2003 Jun 1
46 12811366 A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. 2003 Jun 5
47 12920162 Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. 2003 Sep 2
48 12920168 Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. 2003 Sep 4
49 14508389 Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse. 2003 Oct 1
50 14746343 Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. 2003 Dec 1